United States Food and Drug Administration (USFDA) has concluded audit at Jubilant Pharmova’s wholly-owned subsidiary -- Jubilant Pharma’s subsidiary -- Jubilant Generics’ solid dosage formulations facility on February 2, 2024 at Roorkee site, India. The USFDA has issued 4 observations pursuant to the completion of audit. The company will submit an action plan on the observations.
The company currently supplies only one product to US from Roorkee facility, that contributed less than one percent of Jubilant Pharmova’s 9M’FY24 revenues.
Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.
